F-16438_E
Compound with spectra: 1 NMR
| SpectraBase Compound ID | LLhN2L4KQNb |
|---|---|
| InChI | InChI=1S/C42H66O18/c1-25(18-15-13-11-9-7-5-4-6-8-10-12-14-16-20-29(47)22-28-19-17-21-30(48)33(28)40(53)54)56-41(55)38(57-26(2)45)36(51)34(49)31(23-43)59-42-39(58-27(3)46)37(52)35(50)32(24-44)60-42/h17,19,21,25,31-32,34-39,42-44,48-52H,4-16,18,20,22-24H2,1-3H3,(H,53,54)/t25?,31-,32-,34-,35-,36+,37+,38+,39+,42?/m1/s1 |
| InChIKey | MBAUUCGANHACJM-LQALXXDBSA-N |
| Mol Weight | 859.0 g/mol |
| Molecular Formula | C42H66O18 |
| Exact Mass | 858.424915 g/mol |
| Enantiomer InChIKey | MBAUUCGANHACJM-OJQGCESRSA-N |
| Copyright | Copyright © 2016-2024 W. Robien, Inst. of Org. Chem., Univ. of Vienna. All Rights Reserved. |
|---|---|
| Solvent | C5D5N |
3,6,2'-TRI-O-ACETYL-2-O-OCTADECANOYL-ALPHA,ALPHA-D-TREHALOSE
#3;PORANASIDE-A;(3S,11S)-DIHYDROXYTETRADECANOIC-ACID-11-O-(4-O-ANGELOYL)-ALPHA-L-RHAMNOPYRANOSYL-(1->2)-O-BETA-D-GLUCOPYRANOSYL-(1->2)-BETA-D-QUINOVOPYRANOSIDE
ALPHA-PINENE-7-BETA-O-BETA-D-2-ACETYL-GLUCOPYRANOSIDE
CUPANIOSIDE;1-O-[2'',3'',4''-TRI-O-ACETYL-ALPHA-L-RHAMNOPYRANOSYL-(1->2)-BETA-D-GLUCOPYRANOSYL]-HEXADECANOL
6''-O-ACETYL-BALIBALOSIDE
6'',6'''-O-DIACETYL-BALIBALOSIDE
NONIOSIDE_H;2-O-(6-O-HEXANOYL-BETA-D-GLUCOPYRANOSYL)-6-O-(BETA-D-GLUCOPYRANOSYL)-1-O-OCTANOYL-BETA-D-GLUCOPYRANOSE
JUNIPETRIOLOSIDE-A;3-METHOXY-4-HYDROXYPHENYLPROPANE-7,8-(2',1'-O-BETA-D-GLUCOPYRANOSYL)-7,8,9-TRIOL
CUSCUTIC-ACID-B;(11S)-COVOLVULINOLIC-ACID-11-O-ALPHA-L-RHAMNOPYRANOSYL-(1->3)-O-ALPHA-L-RHAMNOPYRANOSYL-(1->2)-O-BETA-D-GLUCOPYRANOSYL-(1->2)-BETA
6'''-O-ACETYL-BALIBALOSIDE
| Title | Journal or Book | Year |
|---|---|---|
| F-16438s, Novel Binding Inhibitors of CD44 and Hyaluronic Acid | The Journal of Antibiotics | 2006 |
This compound is available in the following databases:
KnowItAll NMR Spectral Library
Author: Wiley
The KnowItAll NMR Spectral Library offers a comprehensive collection of NMR reference spectra, including NMR, CNMR, and XNMR, and covers a wide range of compounds including organics, polymers, monomers, metabolites, and more. Learn more.